{"name":"Soligenix, Inc.","slug":"soligenix","ticker":"SNGX","exchange":"NASDAQ","domain":"soligenix.com","description":"Soligenix, Inc. (SNGX) is a late-stage biopharmaceutical company focused on rare diseases and biodefense. The company's pipeline includes several promising candidates, including SGX301, SGX942, and Mechlorethamine Topical Gel. Soligenix has a strong presence in the biodefense market and is working to expand its reach in rare diseases. With a focus on developing innovative treatments, Soligenix is poised for growth in the coming years.","hq":"Princeton, NJ","founded":0,"employees":"","ceo":"Christopher J. Schaber","sector":"Late-Stage Rare Disease / Biodefense","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$35M","metrics":{"revenue":4500000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"SGX301 (synthetic hypericin)","genericName":"SGX301 (synthetic hypericin)","slug":"sgx301-synthetic-hypericin","indication":"Cutaneous T-cell lymphoma (mycosis fungoides)","status":"phase_3"},{"name":"SGX942","genericName":"SGX942","slug":"sgx942","indication":"Treatment of cutaneous squamous cell carcinoma (cSCC) and other cutaneous malignancies","status":"phase_3"}]}],"pipeline":[{"name":"SGX301 (synthetic hypericin)","genericName":"SGX301 (synthetic hypericin)","slug":"sgx301-synthetic-hypericin","phase":"phase_3","mechanism":"SGX301 is a synthetic hypericin that generates reactive oxygen species upon light activation to destroy targeted cells, particularly in photodynamic therapy applications.","indications":["Cutaneous T-cell lymphoma (mycosis fungoides)","Other dermatologic malignancies and lesions amenable to photodynamic therapy"],"catalyst":""},{"name":"SGX942","genericName":"SGX942","slug":"sgx942","phase":"phase_3","mechanism":"SGX942 is a recombinant human platelet-derived growth factor isoform BB (PDGF-BB) used to promote wound healing.","indications":["Treatment of cutaneous squamous cell carcinoma (cSCC) and other cutaneous malignancies"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Soligenix Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Soligenix reported its financial results for the fourth quarter and full year 2023, highlighting progress in its pipeline and financial performance.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Soligenix Announces Collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to Develop SGX942 for the Treatment of Oral Mucositis","summary":"Soligenix announced a collaboration with the NIAID to develop SGX942 for the treatment of oral mucositis, a common side effect of cancer therapy.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxORFR5b1ZnSjZ3cDBIY2s3UVoxUjl2TjNuUUZJS0h5OFJFRmYtdlRlSHo4WUdwTzZlcWVVb3J0OVFjbTRBdFl3X205WXZZdF9EOTlkUGdjRE9zUGNHNGJoZm9tVjJsbnBCOXNKSTk5S2RVa1BMbjBkM2Y5cWNxSGNrWHpleHhVREVwOGQtVzNmYmRSbEhvQTFXTFkyWUt6S05DcXRwZm5pRDBwcWFGWmVNUWNVVU13NDdJUkdIQzRqVEZucjliZ3BMV24yUm9Bb1VoQUdYNlFlSWpNeE5vM1lPd0pJYzlzSnR3MGtIYVZvRl9qeHN4MWhERDZGV09KT3o5OFhORi11WU1tc2FacGdpUnFKcVp4SUlZM0hZLWM1WVljeFU?oc=5","date":"2026-03-10","type":"regulatory","source":"PR Newswire","summary":"Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - PR Newswire","headline":"Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Produ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE96T2JLMV94YWZ4bUJYbnBLaFRRVXEtWlNDZmdPZFZkLUNvS2ZXczhPZDN2NXJLVkFEZW50alltMUNxQ2tpOG5VeWdtRUJ1enNDT2N6RW5SYlM?oc=5","date":"2025-12-01","type":"pipeline","source":"StocksToTrade","summary":"Top Biotech Penny Stocks to Watch Out for in 2025 - StocksToTrade","headline":"Top Biotech Penny Stocks to Watch Out for in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQc29ka283NUl3UnVKVzlER1lGaDRoaVFtYWZlUjNseUFDYUVsSUREU0R4YmJmZ3kwZ2QzdEphMm10blkzeEhMM0lQLVlzWEpjLW9rUFBmMVpQWnBDczFDVlI1cWlqbzNoNlk2R2FVTk5zWFBnN3RSUzBURDM2WURrOHB3blFxUml2bEE1U21BRG1KaU1MclBmbTFKV2g0R1MzUDZZV1ctakJVTWdWUkhmcGROWXZMRE5HLUFMaUdSdDlNeE9QVy1ISDRkVUJweTJYYmI4T9IB2gFBVV95cUxQX2RhU2d6LThiUlZrRDdEa283elFsdkpTZTYwZ0xuSmg1REJnc05XWmVNTXMteERIQTdPNUFXeVdxZjRYdXB2bk0ydlE0YVpQaU4tZ3h4bHVySDdyZFpFZTZMU2p5WGxWdklUTHBPazBvbmhaRW9Ka3JBRGFBRmhaVTdIektJeHJPYVF3eEpaZmFHNE1HU19rX0JsU0wxN1dpS0N6aV9ONTQ1VXVYMjNmRHh5WVZoUTBPNk1uTU1qQjFscGxzZGprWDBlbjBYdHZXLUJnbkRad3JrUQ?oc=5","date":"2025-08-20","type":"pipeline","source":"simplywall.st","summary":"Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely - simplywall.st","headline":"Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE93eC1WNHJRTXR3OFJFRmlTYmYycVI0SEdGYXBWVVloU3BZckl2WGdjRGhpbmQ0OGsyNVpFeERxWm1WTFRZSzBfMEJuN0pJWVk5NzlaY1hyYWx1TFlFWTFwSFdvcWJybzdOZHV6c3JadUt2ekQ4?oc=5","date":"2025-08-18","type":"pipeline","source":"StocksToTrade","summary":"Soligenix Inc.: An Unexpected Surge? - StocksToTrade","headline":"Soligenix Inc.: An Unexpected Surge?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1TaTdRamNHYmtXNnJxNmZCVVViQm1WWmpwZW1aa0hlWUVRYnZlMDM4dEFBX2YxMWx6REdZS001QXZBbDFSVzFSRWppR0tMdldINUF4OUZLaXlRYm9VXzVQMHFsSWlUdw?oc=5","date":"2025-08-15","type":"pipeline","source":"timothysykes.com","summary":"Top Biotech Penny Stocks to Watch - timothysykes.com","headline":"Top Biotech Penny Stocks to Watch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBvYko2UEhFcllYWU9PVUd2MGR1b05NcW10dXVmbUJUbThZOW9jOU1JaGxwZVF0VWdKWTdqVEVPd21CM0Z5eUpXMGVZT2pPRXlIOERVV1RUOHNST01tcU5ZVXBvMjR5WXBtYXFmblBadUtRdnBt?oc=5","date":"2025-07-31","type":"pipeline","source":"StocksToTrade","summary":"Soligenix Stock Soars: Is A Rebound Imminent? - StocksToTrade","headline":"Soligenix Stock Soars: Is A Rebound Imminent?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPenY2UjBUWTNJLVZnaG9LZ0RsZkNfdkxtV1pkV0JFMDN4WGlPNHVtUGVWbzdvRWk5dlRWS0lWX1puanczYVhUSWl5d1I3dnNoYm9lZXRaVVJkTGsxV044cHMyUkVyYU4tU3JMQVotTXRjYTlpdUFYWXZqQ0VyVDFYQlZmb0xSQ2ctUWJZYWJoTEpsaEt0OVQ5WHFrYzFPZXFaMHA5RDlvdHo4bGJnNG5fZUdOTnBaUVRCdi15OThNcGlSSW14cVMtMXVkS1BVaVhrMS1MY1d1eTBVUS1rQmhLQ2xJTVk?oc=5","date":"2025-07-01","type":"pipeline","source":"PR Newswire","summary":"Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions - PR Newswire","headline":"Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9LZjZrcURQeHRDMXcwdWxwZkFsQjZ6SWxRVzlPU1NJR3pUb0poa2tLTHJhbVFnSmc5V2IwYy1Kdm5rLXVXSkRoV3lOUUYwVDgzR1VJ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"SNGX Stock Price, News & Analysis - Stock Titan","headline":"SNGX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNZWlQcE9KT0R3d0pYYm1WX1dqR2V5c2ZYMndUVTZ2QVJaTG5uUXhsT01sbWNoWXJRcFlQVXFwU1VwdUdXTDJybUZHeFNTdUlMczdfd0kxcUdCcEJveWd4djJQbjhwbVY1Nl9XeUZPcFZXTnBlMDZ2M2ZOU2RqYXVBdUVJd0hrYkFNNWVsVnNWaUgtdF9sYlNIRFhn?oc=5","date":"2024-07-10","type":"trial","source":"MarketBeat","summary":"Uncover Why This Pharma Stock Jumped 400% on Study Update - MarketBeat","headline":"Uncover Why This Pharma Stock Jumped 400% on Study Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE4zdWR3M1EtSi1TTHo4Tm05TVM0djdmai1PQjZhUE5yZ3BGbklQVXhwdnBHRHFpN01NQl9fUTZjMlF0WHptN0FwRmRYMEhOd2UzbUF3UW5tdENzR29tQVc0aFJuTUcyV2F0bFEzeUtJaFRRV3V1M25TLUpSRQ?oc=5","date":"2023-03-17","type":"pipeline","source":"GuruFocus","summary":"Biotex Pharma Investments, Llc Net Worth (2026) - GuruFocus","headline":"Biotex Pharma Investments, Llc Net Worth (2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQaHcxT2ZPN1BhbUVEbVlEeUhHOHp2Ukg5U0xzVUFkc1ZHWmJkV2w5S3lpMFc3ODVLeFJ5dXdJN1Zjal84N1JHNHVUelpmTmlpYWEweUxjeHprb3YwWUE4bTIwRzdWWTNMbmF2c2ZnYU8tWi0zeVltNDBvV3B6b3JuNHpGbWMzMlN6WjV0TGJFWXlHZDdaUWJEbTFRSmFuOGotX2NnWGZRbG5SZ3lpc05LYjJNQS1mdDY5?oc=5","date":"2022-07-27","type":"deal","source":"Streetwise Reports","summary":"Biopharma Co. Signs Exclusive License Deal for Ricin Antigen - Streetwise Reports","headline":"Biopharma Co. Signs Exclusive License Deal for Ricin Antigen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9uRDdKdDZkMGFTV2tYT0V4SFFKYjRqbVBnZVlPRjVCSU1yTTdDU0c3OHBXQ3JfZGsydWNWYWxRZGlCMVRBajk5Zk5KV3VRNVQ2bjUxV05CUkNvb0NR?oc=5","date":"2017-07-21","type":"pipeline","source":"TradingView","summary":"SNGX Stock Price and Chart — NASDAQ:SNGX - TradingView","headline":"SNGX Stock Price and Chart — NASDAQ:SNGX","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Emergent BioSolutions","Valneva SE","Vaxart Inc."],"therapeuticFocus":["Rare Diseases","Biodefense"],"financials":null,"yahoo":null}